Diabetes and immune drugs in kidney disease study
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how diabetes treatments and immune-suppressing drugs affect a process called NETosis, which involves immune cells forming traps. It may help find better ways to treat kidney disease in people with diabetes or immune-related kidney problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diabetes (type 1 or type 2) and are 18 years or older.
- You have not taken SGLT2 inhibitors (like Jardiance) or GLP-1 agonists (like Ozempic) before.
- Or you have chronic kidney disease, especially if it is caused by an immune problem (like ANCA vasculitis).
- You do not have a serious infection, blood cancer, HIV, or hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study looks at kidney diseases caused by the immune system—conditions where your body's defense system mistakenly attacks the kidneys. Researchers will study your medical history, blood, and urine to better understand these diseases and potentially improve treatment.
This trial looks at whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help protect the kidneys and heart in people with chronic kidney disease or type 2 diabetes. If you have either condition, you might be able to join.
This study looks at how the immune system works in people with diabetic kidney disease. It tests whether certain blood pressure medicines can help protect the kidneys.
This study collects and studies kidney tissue (from a biopsy or surgery) from people with diabetes-related kidney disease to learn more about the condition. You may be able to help if you've already had a kidney biopsy or certain kidney surgeries.
This study tests an investigational drug called ALN-ANG3 to see if it can help people with diabetic kidney disease. The drug may reduce kidney damage and slow down the loss of kidney function. If you join, you will get the study drug or a placebo (a dummy shot) and be followed by a study doctor.
This study looks at how SGLT2 inhibitor medications (a type of diabetes drug) protect the kidneys in people with type 2 diabetes and chronic kidney disease. Researchers will use MRI scans to understand the protective effects, which could help improve future treatments.
Hear when a new Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.